Pediatric anesthesia & critical care
Respiratory Syncytial Virus and US Pediatric Intensive Care Utilization
An erratum to this article was published (JAMA Netw Open, 3 Mar 2025 ↗)
Authors' conclusion
The findings of this retrospective cross-sectional study of RSV and US pediatric intensive care utilization suggest that if 65% to 85% of eligible children received RSV prevention, an estimated 2.1% to 2.8% reduction in pediatric ICU encounters and an estimated 4.5% to 5.9% reduction in pediatric ICU days could be achieved.
Study context
- Population
- US children (aged >1 day and <18 years) admitted to an intensive care unit (ICU), January 1, 2017, to June 1, 2023
- Participants
- 119,782 children · 53 hospitals
- Exposure
- ICU encounters with respiratory syncytial virus (RSV) vs without RSV
- RSVn = 13,702
- Outcome
- ICU encounters with RSV and ICU encounters with RSV eligible for RSV prevention
Methodological detailsnational electronic health record database, Data from Oracle Cerner RealWorld Data
- National electronic health record database
- Data from Oracle Cerner RealWorld Data
Main finding
As reported in the abstract
ICU encounters with RSV
RSV
11.4%
13 702
- RSV encounters eligible for prevention
- 38.6% (5217)
- Eligible RSV encounters as share of total ICU encounters
- 4.4%
Observational data: associations, not effects.
Further findings
Positive pressure ventilation
P < 0.001
Vasoactive medications
P < 0.001
ICU days
- ICU days accounted for by RSV encounters
- 21.1% (109 334)
- RSV ICU days eligible for prevention
- 43.8% (47 888)
- Eligible RSV ICU days as share of total ICU days
- 9.2%
Original publication
Respiratory Syncytial Virus and US Pediatric Intensive Care Utilization. JAMA Netw Open. Published 1 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →